STTK 240816 5.00C (STTK240816C5000) Stock Options, News & Quotes

0.35
0.000.00%

15min DelayClose Aug 2 15:56 ET

0.00High0.00Low

SymbolStock Name

Latest PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Trytosaveabit

Jun 26 16:05

Insider buy

$Shattuck Labs(STTK.US)$ Officer Schreiber Taylor purchased 14,400 shares of common stock on Jun 26, 2024 at an average price of $3.473 for a total value of $50,011.2.

Trytosaveabit

Jun 14 05:34

Update

$Shattuck Labs(STTK.US)$ Shattuck Labs, Discloses Updated Interim Data From Phase 1B Dose Expansion Clinical Trial Of SL-172154 In Combination With Azacitidine In Frontline Higher-Risk Myelodysplastic Syndromes And TP53 Mutant Acute Myeloid Leukemia Patients
Benzinga
The company observed 67% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete remission (CR)/marrow complete remission (mCR) rate of 58% and median overall survival had no...

Trytosaveabit

Jun 10 06:39

News

$Shattuck Labs(STTK.US)$ Benzinga· 2 mins ago
Shattuck Labs Granted Orphan Drug Designation By FDA For SL-172154 In Acute Myeloid Leukemia

Jaguar8

Apr 9 15:08

$Shattuck Labs(STTK.US)$
NEWS
Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024
Shattuck Labs, Inc. reveals preclinical data at AACR Annual Meeting 2024 showing TRIM7 inhibition can combat immune checkpoint therapy resistance. TRIM7 inhibitors may reverse acquired resistance to PD-1/L1 blockade, potentially benefiting cancer patients.

Trytosaveabit

Feb 13 05:06

Update

$Shattuck Labs(STTK.US)$ Shattuck Labs Announces Drug Discovery Collaboration With Ono Pharmaceutical, For Bifunctional Fusion Proteins Targeting Certain Autoimmune And Inflammatory Disease Pathways, Shattuck To Receive Upfront And Be Eligible For Milestone Payments Of Upto $227M